Simon Tate
Director/Miembro de la Junta en ELIEM THERAPEUTICS, INC. .
Fortuna: - $ al 31/05/2024
Perfil
Simon Nicholas Tate is the founder of Convergence Pharmaceuticals Ltd.
He currently holds the position of Independent Director at Eliem Therapeutics, Inc. and is a Venture Partner at Bridge Valley Ventures LLP.
In the past, he has worked as a Managing Director at Intermediate Capital Group Plc, Non-Executive Director at Calchan Holdings Ltd.
and Calchan Ltd., Vice President & Head-Pain Therapeutic Area at Biogen, Inc., and VP-Pain & Epilepsy Discovery Performance Unit at GlaxoSmithKline, Inc. He graduated from the University of Dundee.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
-.--% | 10/05/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Cargos activos de Simon Tate
| Empresas | Cargo | Inicio |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/02/2019 |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Inversor de Capital Privado | - |
Antiguos cargos conocidos de Simon Tate.
| Empresas | Cargo | Fin |
|---|---|---|
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Fundador | 12/04/2018 |
| INTERMEDIATE CAPITAL GROUP PLC | Corporate Officer/Principal | - |
Calchan Ltd.
 Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Director/Miembro de la Junta | - |
| BIOGEN INC. | Corporate Officer/Principal | - |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Formación de Simon Tate.
| University Of Dundee | Graduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| INTERMEDIATE CAPITAL GROUP PLC | Finance |
| Empresas privadas | 5 |
|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Calchan Holdings Ltd.
 Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Calchan Holdings Ltd. develops novel oral state-dependent calcium channel modulators for chronic pain. The company was founded on February 25, 2011 and is headquartered in London, the United Kingdom. | Health Technology |
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Calchan Ltd.
Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Bridge Valley Ventures LLP
Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Finance |
- Bolsa de valores
- Insiders
- Simon Tate
